Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HTR6 | P50406 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12898166 | 0.93 | MAPK14 (0.46) | POLBTP53HTR6MEN1KMT2A | |
| SCHEMBL12898168 | 0.90 | RAB9A (0.46) | TP53HTR6MEN1KMT2ARAB9A | |
| SCHEMBL12898178 | 0.87 | POLB (0.51) | POLBTP53HTR6MEN1KMT2A | |
| SCHEMBL12898169 | 0.86 | LMNA (0.50) | POLBTP53HTR6MEN1KMT2A | |
| SCHEMBL1268088 | 0.86 | MAPK1 (0.46) | POLBHTR6MEN1KMT2AREN | |
| SCHEMBL12898215 | 0.85 | HTR6 (0.44) | POLBHTR6MEN1KMT2AREN | |
| SCHEMBL1269211 | 0.84 | MAPK1 (0.47) | HTR6MEN1KMT2AREN | |
| SCHEMBL12898182 | 0.84 | HTR6 (0.43) | POLBTP53HTR6MEN1KMT2A | |
| SCHEMBL12898170 | 0.84 | ALDH1A1 (0.55) | POLBTP53HTR6 | |
| SCHEMBL1268273 | 0.84 | HTR6 (0.42) | POLBTP53HTR6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | GSK3B, GSK3A, GSKIP | POLB 1772/4885TP53 1224/4885HTR6 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.